

RESEARCH

Open Access

Functional consequences of copy number variants in miscarriage

Jiadi Wen^{1,2†}, Courtney W Hanna^{2,3†}, Sally Martell², Peter CK Leung^{2,4}, Suzanne ME Lewis³, Wendy P Robinson^{2,3}, Mary D Stephenson⁵ and Evica Rajcan-Separovic^{1,2*}

Abstract

Background: The presence of unique copy number variations (CNVs) in miscarriages suggests that their integral genes have a role in maintaining early pregnancy. In our previous work, we identified 19 unique CNVs in ~40% of studied euploid miscarriages, which were predominantly familial in origin. In our current work, we assessed their relevance to miscarriage by expression analysis of 14 genes integral to CNVs in available miscarriage chorionic villi. As familial CNVs could cause miscarriage due to imprinting effect, we investigated the allelic expression of one of the genes (*TIMP2*) previously suggested to be maternally expressed in placenta and involved in placental remodelling and embryo development.

Results: Six out of fourteen genes had detectable expression in villi and for three genes the RNA and protein expression was altered due to maternal CNVs. These genes were integral to duplication on Xp22.2 (*TRAPPC2* and *OFD1*) or disrupted by a duplication mapping to 17q25.3 (*TIMP2*). RNA and protein expression was increased for *TRAPPC2* and *OFD1* and reduced for *TIMP2* in carrier miscarriages. The three genes have roles in processes important for pregnancy development such as extracellular matrix homeostasis (*TIMP2* and *TRAPPC2*) and cilia function (*OFD1*). *TIMP2* allelic expression was not affected by the CNV in miscarriages in comparison to control elective terminations.

Conclusion: We propose that functional studies of CNVs could help determine if and how the miscarriage CNVs affect the expression of integral genes. In case of parental CNVs, assessment of the function of their integral genes in parental reproductive tissues should be also considered in the future, especially if they affect processes relevant for pregnancy development and support.

Keywords: Miscarriage, Copy number variation, *TIMP2*, *OFD1*, *TRAPPC2*, Gene expression

Background

Genetic factors, such as single gene defects and chromosomal abnormalities, are a common cause of miscarriage [1-3]. Their identification is important for informed reproductive decisions and counselling and is the key goal of reproductive genetics [4,5]. The detection of chromosomal abnormalities has been recently revolutionized with the development of chromosome microarray analysis (CMA) which facilitates the detection of large scale and subtle chromosomal microdeletions and microduplications (DNA copy number variants or CNVs). CMA is

based on the assessment of DNA directly obtained from tissues and thus minimizes the negative impact of tissue culture artefacts and failure associated with traditional cytogenetic analysis of miscarriages.

Due to its many benefits, including improved resolution and diagnostic yield, CMA is now considered a first line test for subjects with postnatal developmental delay and congenital abnormalities [6,7]. It identifies clinically relevant CNVs in 10-15% of chromosomally normal cases, with the majority of CNVs undetectable by routine karyotyping. In contrast, array studies of miscarriages are still rare, and no more than 3000 cases worldwide were reported [3]. Most of the miscarriage cases (2392) were described in the recent publication by Levy et al. [8], which reported putatively causative CNVs in 1.6% of chromosomally normal cases. These CNVs were defined as >5 Mb or overlapping with critical

* Correspondence: eseparovic@cw.bc.ca

†Equal contributors

¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver V6T 2B5, Canada

²Child & Family Research Institute, Vancouver V5Z 4H4, Canada

Full list of author information is available at the end of the article

regions causing or predisposing to viable microdeletion/duplication syndromes.

Interestingly, the majority of CNVs identified so far in miscarriages with a normal karyotype were familial in origin. CNVs inherited from normal parents are generally considered less likely to be causative of an abnormal phenotype, however, they can be pathogenic if they i) uncover a mutation within the intact allele of the developmental gene in the conceptus, ii) contain genes with variable expressivity or penetrance iii) involve imprinting (parent of origin dependent) genes. In addition, parental CNVs could still lead to miscarriage if they affect genes required for normal parental reproductive function, including, for example, genes required for placenta function, maternal preparation for and maintenance of pregnancy and genomic stability of the sperm. These processes are essential for successful pregnancy outcome [9], but may not necessarily impair parents' overall health status and can demonstrate pathogenic characteristics only at the time of pregnancy. Recently, Nagirnaja et al. [10], suggested that a CNV from 5p13.3 chromosomal region is enriched in women with recurrent pregnancy loss (RPL) in comparison to fertile controls and could represent a risk factor for pregnancy complications, as it contains genes predominantly expressed in placenta.

We have recently performed CMA analysis of miscarriages from couples with RPL and sporadic miscarriages with embryoscopy findings [11,12]. Unique CNVs not reported in Database of Genomic Variants were noted in ~40% of miscarriages and were predominantly parental in origin, making their interpretation more challenging. In order to further investigate the potential role of these CNVs in miscarriage we performed functional analysis (RNA and protein expression) of genes integral to miscarriage CNVs, using chorionic villi from miscarriages from 6 families with RPL, reported in our previous work. Our study shows changes in RNA/protein expression for 3/14 tested genes from maternal CNVs, which could be of relevance for miscarriage due to their role in processes important for growth of the conceptus and/or maternal preparation for and support of pregnancy. Functional studies of miscarriage CNVs could therefore help identify miscarriage candidate genes, but should be accompanied with functional studies of CNVs in reproductive tissues of carrier parents.

Results

Expression of genes integral to CNVs in miscarriage cell cultures

Three genes, *OFDI*, *TRAPPC2* and *TIMP2* out of 14 selected for expression analysis had altered mRNA and protein expression in cultured miscarriage chorionic villi cells (Table 1 and Figures 1 and 2). For *NDUFA2*, *CHSY3*

and *PRMT3* (Table 1) the expression in control pregnancies and miscarriages with CNVs was comparable. The remaining genes assayed had either very low or no expression in cultured chorionic villi from controls (*PARK*, *LIPC*, *CTNNA3*, *EGFL6*, *GPM6B*, *RAB9A*, *POU6F2* and *C7orf10*) and were not assessed in miscarriages.

OFDI and *TRAPPC2* are integral to a CNV on Xp22.2 (duplication with breakpoints from 13415099–13745233) identified by Agilent 105 k array (Figure One in Rajcan-Separovic et al. [12]) in female 09–1 who had 6 miscarriages (current paper, Additional file 1: Table S1). Two of her 6 miscarriages had array analysis: male miscarriage 09-3A had a normal array result, while female miscarriage 09-3B inherited the maternal Xp22.2 CNV. These two miscarriages were available for functional analysis. Increased RNA and protein expression for *OFDI* and *TRAPPC2* was detected in 09-3B (Figure 1), while the remainder of the genes from the Xp22.2 CNV (*EGFL6*, *GPM6B*, and *RAB9A*) had low or undetectable expression in control ET cell cultures and were not evaluated in 09-3B (Table 1). Random chromosome X inactivation was identified in 09-3B, while the mother's chromosome X inactivation status was uninformative [12].

The CNV disrupting the *TIMP2* gene mapped to 17q25.3 (duplication with breakpoints from 74,381,287 -74,466,887) and was detected in female 6–1 and in 4/5 available miscarriages, as reported previously (Figure Two in Rajcan-Separovic et al. [12]). Cell cultures from chorionic villi were available from four miscarriages (06-3A, C, D which contained the CNV and 06-3E which did not). The three miscarriages with the *TIMP2* CNV (06-3A, C and D) showed a ~50% decrease in mRNA and protein expression in comparison to four control elective terminations (ET 15, 17, 18 and 20). A ~2-fold increase of *TIMP2* mRNA and protein was noted in the fourth miscarriage (06-3E), which did not carry the *TIMP2* CNV (Figure 2).


TIMP2 Allelic expression analysis

Based on previous reports suggesting preferential maternal expression of *TIMP2* in placenta [13], we tested the parent-of-origin specific expression of *TIMP2* in control ET and in miscarriages from female 06–1 to determine if the CNV affected the *TIMP2* allelic expression. Monoallelic expression of the maternal allele was detected in 2 of 3 informative miscarriages (06-3C with and 06-3E without the CNV, Figure 3) while a close to biallelic expression (~60%) was noted in the third miscarriage (06-3D) which was trisomic for chromosome 16 and contained the *TIMP2* CNV. Monoallelic expression of the maternal allele was also noted in two of the seven informative ET samples heterozygous for the polymorphic rs2277698 G/A SNP in exon 3 (out of 35 genotyped). The cells from the remaining 5 control and informative ETs had biparental expression.

Table 1 CNV gene analysis

| Samples | Miscarriage | Locus | Breakpoint | CNV size (kb) | Type of CNV and origin | Gene picked for expression (type of CNV abnormality) | mRNA expression in control elective terminations/miscarriage that carries the CNV | Protein expression | | | |
|---|-----------------------------|---------------------|---------------------|---------------|-------------------------------------|--|---|--------------------------|----------------------------------|--|--|
| Miscarriages from reference Rajcan-Separovic et al. [12] | 03-3A | 6q26 | 162126633-162271770 | 145 | loss-pat | PARK2 (loss involves part of exon and intron) | N/not attempted | | | | |
| | 05-3A | 5q12.1 | 60407026-60464658 | 58 | loss-pat | NDUFAF2 (loss involves exon 3) | yes/no difference between CNV carriers and controls | | | | |
| | 06-3A,B,C and D (not in 3E) | 17q25.3 | 74381287-74466887 | 86 | gain-mat | TIMP2 (gain involves exon1,2) | yes/decrease in CNV carriers | decreased | | | |
| | 06-3E | 15q22.1 | 56487120-56562873 | 76 | loss-pat | LIPC (loss of exon1) | N/not attempted | | | | |
| | 07-3A | 10q21.3 | 67992425-68064617 | 72 | loss-mat | CTNNA3 (loss involves exon11) | N/not attempted | | | | |
| | 09-3B (not in 3A) | Xp22.2 | 13415099-13745233 | 33 | gain-mat | EGFL6 (complete gain) | N/not attempted | | | | |
| | | | | | | GPM6B (almost complete gain) | N/not attempted | | | | |
| | | | | | | OFD1 (complete gain) | yes/increase in CNV carrier | increased in CNV carrier | | | |
| | | | | | | RAB9A (complete gain) | N/not attempted | | | | |
| | | | | | | TRAPPC2 (complete gain) | yes/increase in CNV carrier | increased in CNV carrier | | | |
| 10-3A | 5q23.3 | 129388119-129441487 | 53 | loss-pat | CHSY3 (CSS3) (loss involves intron) | yes/no difference between CNV carrier and controls | | | | | |
| | | | | | 11p15.1 | 20442396-20559837 | 117 | Gain-pat | PRMT3 (gain involves exon9-11) | yes/no difference between CNV carrier and controls | |
| | | | | | 7p14.1 | 39470588-39647671 | 177 | Gain-mat | POU6F2 (gain involves last exon) | N/not attempted | |
| C7orf10 (complete gain) | N/not attempted | | | | | | | | | | |

N = expression in control villi tissue low or not detectable, the expression in miscarriage therefore not attempted.



Discussion

In this study we explored further the miscarriage CNVs we identified in our previous work by testing the expression levels of their integral genes in available miscarriage tissues with CNVs. Three genes integral to maternal CNVs had altered expression in miscarriages consistent with genomic alternation caused by the CNV.

TRAPPC2 and *OFD1* had increased RNA and protein expression in miscarriage 9-3B with a gain of Xp22.2. *TRAPPC2* has a role in procollagen transportation [14] while *OFD1* regulates cilia function [15]. Collagens are the main components of extracellular matrix (ECM) and provide structural support for the tissues, but also play important roles in cell growth, differentiation, adhesion, and migration [16,17]. The dysfunction of *OFD1*, through abnormal ciliogenesis, results in defects in sonic hedgehog (Shh) and canonical Wnt signaling pathways [15,18-20] which are linked to abnormal implantation and embryonic development [21-23]. Although the mis-expression of *TRAPPC2* and *OFD1* could potentially explain miscarriage 9-3B, the Xp22.2 CNV was not

present in miscarriage 09-3A, and therefore cannot be associated with all the pregnancy losses of female 09-1. Instead, the unifying cause of her miscarriages could be the effect of the CNV on maternal *OFD1* and *TRAPPC2* gene expression, particularly because of the reports of abnormal uterine collagen content resulting in pregnancy loss [24,25]. It would be of interest to explore the expression of these genes in the decidua of female 9-1. Unfortunately this tissue was not available for analysis.

TIMP2 is the third gene that showed altered expression in miscarriages and is known to inhibit matrix metalloproteases (MMPs), which degrade extra cellular matrix (ECM), and have a critical role in tissue remodeling and angiogenesis in placenta/endometrium [26-29]. Expression of *TIMP2* was reduced in miscarriages with the CNV, possibly because the CNV (duplication) disrupts the 5' end of the gene and causes structural alternations in the genomic region of *TIMP2*. It has been previously observed that the genomic position of regulatory elements in the *TIMP2* promoter (AP-1) affects the gene expression [30]. However, the CNV appears not to be the sole cause





Figure 2 mRNA and protein expression of *TIMP2* in primary culture of human chorionic villi. ET15, 17, 18 and 20 indicate control cell cultures from elective terminations (n = 4). 06-3A, C, D and E indicate miscarriages of the female 06-1 (n = 4). **(A)** mRNA and **(B)** protein values for *TIMP2* expression were normalized to the corresponding β -actin mRNA levels. The results derived from at least three repeats of each sample and the mean level of each sample is represented in the scatter graph. The difference between the four control samples and the three CNV carrier miscarriages, as two groups, has been evaluated by student t-test (*, p < 0.05).

of recurrent miscarriage in this family as *TIMP2* expression was also altered (increased) in the miscarriage without the CNV. It is conceivable that, due to the CNV, the expression of *TIMP2* is also abnormal (reduced) in the endometrium/decidua of female 6-1 and could impair pregnancy development. This is of interest considering that decidual *TIMP2* has a role in regulating trophoblast invasion by modulating trophoblast *MMP* and *TIMP2* expression [31], and in particular inhibiting trophoblast *TIMP2* expression. In keeping with the possibility of the effect of the maternal and/or pregnancy CNV on *TIMP2* function are the pathology findings for six out of ten miscarriages from female 6-1 which demonstrated morphologic abnormalities of the maternal vasculature (intimal hyperplasia of maternal vessels) and/or placenta (perivillous fibrin deposits) [12] (Additional file 1: Table S1).

Familial CNVs are frequently hypothesised to cause an adverse outcome of the pregnancy if they contain or

disrupt imprinting genes. Previous reports suggested that *TIMP2* is an imprinted gene with preferential maternal expression in placenta. This was based on observations of reduced expression in placenta from complete moles [13], and overexpression of the maternal copy in a mouse model of RPL [32]. We were therefore interested in finding out if the maternal CNV, disrupting the *TIMP2* gene, affects its allelic expression in miscarriages that carry the CNV. Our parent of origin expression analysis demonstrated biallelic expression in most cases including one miscarriage with the CNV. However, it appears that the regulation of *TIMP2* allelic expression is complex, as it was preferentially maternal in 2/3 miscarriages and 2/7 ETs. It is possible that the allelic expression of this gene is affected by the degree of clonality after placental cell culture, the ratio of methylation of CpG islands (Chernov, et al. [33]), or additional genetic polymorphisms affecting gene expression on one or



the other copy. Comprehensive analysis of epigenetic marks at the *TIMP2* gene promoter region(s) in relation to expression is needed to elucidate whether this gene is indeed imprinted and which modifications are important for regulation of gene expression.

Conclusion

Overall, our findings underscore the need for additional functional characterization of miscarriage CNVs to develop an understanding of the effect of their integral genes on pregnancy development. These studies can be challenging due to lack of miscarriage cell cultures or RNA/protein for functional studies in miscarriages and lack of parental reproductive tissues in cases with parental CNVs. Collection of reproductive tissues (e.g. maternal decidua) for functional analysis would be desirable in future miscarriage CNV analysis. As more miscarriage associated CNVs and genes are identified, their individual and collective role in miscarriage will become more apparent.

Methods

Subjects

Control pregnancy and miscarriage tissues

Control chorionic villus samples were obtained from first trimester elective terminations (ET) of pregnancy for social reasons by dilation and curettage (6–12 weeks of gestation). The control ET had no evidence of aneuploidy as determined by multiplex ligation dependent probe amplification (MLPA) [34]. Four ET tissues were used for tissue culture, as previously described [35].

Thirty five uncultured ET tissues were assessed for allelic expression analysis of *TIMP2* gene (see below).

Chorionic villus cell cultures of 10 miscarriages from 6 families (03,05,06,07,09 and 10 as described in Table 1 in the current paper and in Rajcan-Separovic et al. [12]) were available for RNA and protein expression analysis. Culture conditions were as for the ET tissues [35].

Maternal contamination has been ruled out in all ET and miscarriage cultures by examining microsatellite markers, using standard protocols [12,36]. The use of parental blood samples, control and miscarriage tissues was approved by the Committee for Ethical Review of Research involving Human Subjects, University of British Columbia and Institutional Review Board of the University of Chicago. All subjects gave written informed consent for these studies.

Expression analysis

RNA, DNA and protein extraction

Total RNA, DNA and protein were extracted from the chorionic villus (CV) cell cultures simultaneously using commercially available kits (AllPrep DNA/RNA Mini kit, Qiagen) according to the manufacturer's instructions. The purity and concentration of total RNA, DNA and protein present in each of these extracts were quantified using a NanoDrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, USA).

For allelic expression analysis, RNA and DNA were extracted from ET tissue stored in RNA later. Genomic DNA (gDNA) was used to obtain fetal genotype and informative (heterozygous) samples were used for the allelic expression analysis.

cDNA synthesis

Aliquots of the total RNA extracts (~500 ng) prepared from the CV cell cultures were subsequently reverse-transcribed into cDNA using GeneAmp Gold RNA PCR Core Kit (Applied Biosystems, Melbourne, Australia). High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Melbourne, Australia) was used to generate cDNA from 35 ET tissues for *TIMP2* allelic expression analysis.

Real-time quantitative (q)PCR

RNA expression analysis was performed in cultured chorionic villi from miscarriages with CNVs and four ETs. Fourteen genes integral to the miscarriage CNVs were selected, and bioinformatics tools and publicly available human genome databases (Ensemble Genome Browser, UCSC) are used to select appropriate primers. The genes for expression analysis were selected based on the availability of cells/RNA/protein from miscarriages that contained their copy number change and included: *PARK2*, *NDUFAF2*, *TIMP2*, *LIPC*, *CTNNA3*, *EGFL6*, *GPM6B*, *OFD1*, *RAB9A*, *TRAPPC2*, *CHSY3*, *PRMT3*, *POU6F2*, and *C7orf10* (Table 1). The nucleotide sequences for primers specific for the 14 genes or the housekeeping gene β -actin were designed using Primer Express software (Perkin-Elmer Applied Biosystems) and purchased from Integrated DNA Technologies (IDT). Primer sequences for tested regions are listed in Additional file 1: Table S2. The first-strand cDNA generated from the chorionic villi cells served as a template for qRT-PCR using the ABI PRISM 7300 Sequence Detection System (Perkin-Elmer Applied Biosystems) equipped with a 96-well optical reaction plate for primers specific for 14 selected genes and the housekeeping gene, β -actin. Real-time qPCR was performed as previously described [37].

Western blot analysis

We detected changes in RNA expression for 3 genes in miscarriages: *OFD1* and *TRAPPC2* from Xp22 CNV (present in female 09–1 and one out of two miscarriages) and *TIMP2* from 17q25 CNV (present in female 6–1 and 4/5 miscarriages). Protein expression analysis for these genes was performed using polyclonal antibodies directed against human *OFD1* (Abcam, No. ab97861, ON, Canada), *TRAPPC2* (generous gift from Dr De Matteis, Italy) and *TIMP2* (NovusBiologicals, No. NB100-92000, Littleton, US). To standardize the amounts of protein loaded into each lane, the blots were reprobed with a monoclonal antibody directed against human β -actin (Novus Biologicals, Littleton, US). The ECL Western Blotting system was used to detect the amount of each antibody bound to antigen and the resultant photographic films were analyzed by UV

densitometry (GE Healthcare Life Sciences, Pittsburgh, USA). The absorbance values obtained for *OFD1*, *TRAPPC2* or *TIMP2* were then normalized relative to the corresponding β -actin absorbance value. The average of *OFD1*, *TRAPPC2* and *TIMP2* protein expression were obtained from 3 independent replicates for each miscarriage and ET control samples.

Allelic expression analysis of *TIMP2* gene

We assessed the effect of the CNV on allelic expression in miscarriages from female 6–1 rather than methylation since the *TIMP2* promoter is unmethylated in cervix and blood [38], human term placenta (unpublished data) and mouse placenta throughout pregnancy [39]. Three heterozygous SNPs were identified within the exons of the *TIMP2* gene using UCSC Genome Browser: rs7503726 and rs2277698 in the 5'UTR and rs2277698 within exon 3. Genotyping assays were designed for all three SNPs, using the PSQ Assay Design Software; with successful targeted amplification for only the rs2277698 G/A SNP in exon 3 (heterozygosity = 0.241 ± 0.250) (Additional file 1: Table S3). Genotyping was done on the Pyromark MD machine using the PyroGold SQA reagent kit (Qiagen, Hilden, Germany), using gDNA from placenta to obtain fetal genotypes. Genotyping was performed on DNA from 35 ET samples and 5 miscarriages from female 6–1 with RPL, 4/5 carried the *TIMP2* CNV. 7/35 ET and 3/5 tested miscarriages were informative (heterozygous). Parental origin of the rs2277698 alleles in ET and miscarriage samples was determined by assessing maternal genotypes in DNA extracted from the placental decidua or blood. The sequencing primer used for the gDNA assay (Additional file 1: Table S3), was then used to assess whether there was allelic bias in expression of *TIMP2* in the cDNA, after cDNA-specific amplification. The relative percentage of expressed alleles was obtained using the allelic quantification setting on the Pyromark MD software, and averaging of two independent replicates for each sample.

Statistical analysis

All statistical tests were performed using the VassarStats: Statistical Computation Web Site (Vassar College, Poughkeepsie, USA), R Statistical Software 2.12.0 (The R Project for Statistical Computing, Auckland, New Zealand) or GraphPad Prism 4 computer software (GraphPad, San Diego, CA). Student's t-test was used to determine significant differences in transcript levels between the four miscarriages from family 6 with available cultures (3 that carry the *TIMP2* CNV and one without it) and four control ETs. $p < 0.05$ was considered significant. Significance between the variances of the two groups was determined using F-test.

The absorbance values obtained from the real-time qPCR products and the photograph generated by

Western blotting were subjected to statistical analysis using GraphPad Prism 4 computer software (GraphPad, San Diego, CA). Statistical significance between the absorbance values were assessed by the analysis of variance (ANOVA), with $p < 0.05$ considered significant. Comparison of the means between patients and controls were determined using Dunnett's test. The results are presented as the mean \pm S.E.M. from at least three independent experiments.

Additional file

Additional file 1: Table S1. Pathology description of the recurrent miscarriages with familial CNV. **Table S2.** Primer sequences for Real-time qPCR. **Table S3.** Primers used to assess allelic expression of TIMP2.

Competing interests

The authors declare that they have no competing interest.

Authors' contributions

ERS: Conception, design, interpretation of data, drafting the article and revising it critically for important intellectual content. JW, CWH: designed and conducted experiments, analysed and interpreted data, drafted and revised the article. SM: conducted experiment, analysed and interpreted data. PCKL, SMEL, WPR, MS: revised the article for important intellectual content. All authors read and approve the final manuscript.

Acknowledgements

The study was funded by CIHR (grant MOP 106467) and MSFHR Career Scholar salary award to ERS. We appreciate the generous gift of the TRAPCC2 antibody from Dr De Matteis (Telethon Institute of Genetics and Medicine, Via Pietro Castellino 111, Naples 80131, Italy).

Author details

¹Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver V6T 2B5, Canada. ²Child & Family Research Institute, Vancouver V5Z 4H4, Canada. ³Department of Medical Genetics, University of British Columbia, Vancouver V6T 1Z3, Canada. ⁴Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver V6Z 2 K5, Canada. ⁵Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago 60612, USA.

Received: 13 December 2014 Accepted: 9 January 2015

Published online: 31 January 2015

References

- Warren JE, Silver RM. Genetics of pregnancy loss. *Clin Obstet Gynecol.* 2008;51(1):84–95.
- Group ECW. Genetic aspects of female reproduction. *Hum Reprod Update.* 2008;14(4):293–307.
- van den Berg MM, van Maarle MC, van Wely M, Goddijn M. Genetics of early miscarriage. *Biochim Biophys Acta.* 2012;1822(12):1951–9.
- Stembalska A, Slezak R, Pesz K, Gil J, Sasiadek M. Prenatal diagnosis—principles of diagnostic procedures and genetic counseling. *Folia Histochem Cytobiol.* 2007;45 Suppl 1:S11–6.
- Stephenson M, Kutteh W. Evaluation and management of recurrent early pregnancy loss. *Clin Obstet Gynecol.* 2007;50(1):132–45.
- Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet.* 2010;86(5):749–64.
- Kang JU, Koo SH. Evolving applications of microarray technology in postnatal diagnosis (review). *Int J Mol Med.* 2012;30(2):223–8.
- Levy B, Sigurjonsson S, Pettersen B, Maisenbacher MK, Hall MP, Demko Z, et al. Genomic imbalance in products of conception: single-nucleotide polymorphism chromosomal microarray analysis. *Obstet Gynecol.* 2014;124(2 Pt 1):202–9.
- Larsen EC, Christiansen OB, Kolte AM, Macklon N. New insights into mechanisms behind miscarriage. *BMC Med.* 2013;11:154.
- Nagirinaja L, Palta P, Kasak L, Rull K, Christiansen OB, Nielsen HS, et al. Structural genomic variation as risk factor for idiopathic recurrent miscarriage. *Hum Mutat.* 2014;35(8):972–82.
- Rajcan-Separovic E, Qiao Y, Tyson C, Harvard C, Fawcett C, Kalousek D, et al. Genomic changes detected by array CGH in human embryos with developmental defects. *Mol Hum Reprod.* 2010;16(2):125–34.
- Rajcan-Separovic E, Diego-Alvarez D, Robinson WP, Tyson C, Qiao Y, Harvard C, et al. Identification of copy number variants in miscarriages from couples with idiopathic recurrent pregnancy loss. *Hum Reprod.* 2010;25(11):2913–22.
- Okamoto T, Niu R, Yamada S, Osawa M. Reduced expression of tissue inhibitor of metalloproteinase (TIMP)-2 in gestational trophoblastic diseases. *Mol Hum Reprod.* 2002;8(4):392–8.
- Venditti R, Scanu T, Santoro M, Di Tullio G, Spaar A, Gaibisso R, et al. Sedlin controls the ER export of procollagen by regulating the Sar1 cycle. *Science.* 2012;337(6102):1668–72.
- Ferrante MI, Zullo A, Barra A, Bimonte S, Messaddeq N, Studer M, et al. Oral-facial-digital type I protein is required for primary cilia formation and left-right axis specification. *Nat Genet.* 2006;38(1):112–7.
- Aplin AC, Fogel E, Zorzi P, Nicosia RF. The aortic ring model of angiogenesis. *Methods Enzymol.* 2008;443:119–36.
- Heino J. The collagen family members as cell adhesion proteins. *Bioessays.* 2007;29(10):1001–10.
- Hunkapiller J, Singla V, Seol A, Reiter JF. The ciliogenic protein oral-facial-digital 1 regulates the neuronal differentiation of embryonic stem cells. *Stem Cells Dev.* 2011;20(5):831–41.
- Cortellino S, Wang C, Wang B, Bassi MR, Caretti E, Champeval D, et al. Defective ciliogenesis, embryonic lethality and severe impairment of the Sonic Hedgehog pathway caused by inactivation of the mouse complex A intraflagellar transport gene *Ift122/Wdr10*, partially overlapping with the DNA repair gene *Med1/Mbd4*. *Dev Biol.* 2009;325(1):225–37.
- Ferrante MI, Romio L, Castro S, Collins JE, Goulding DA, Stemple DL, et al. Convergent extension movements and ciliary function are mediated by *ofd1*, a zebrafish orthologue of the human oral-facial-digital type 1 syndrome gene. *Hum Mol Genet.* 2009;18(2):289–303.
- Harman RM, Cowan RG, Ren Y, Quirk SM. Reduced signaling through the hedgehog pathway in the uterine stroma causes deferred implantation and embryonic loss. *Reproduction.* 2011;141(5):665–74.
- Chen Q, Zhang Y, Lu J, Wang Q, Wang S, Cao Y, et al. Embryo-uterine cross-talk during implantation: the role of Wnt signaling. *Mol Hum Reprod.* 2009;15(4):215–21.
- Mohamed OA, Dufort D, Clarke HJ. Expression and estradiol regulation of Wnt genes in the mouse blastocyst identify a candidate pathway for embryo-maternal signaling at implantation. *Biol Reprod.* 2004;71(2):417–24.
- Diao H, Aplin JD, Xiao S, Chun J, Li Z, Chen S, et al. Altered spatiotemporal expression of collagen types I, III, IV, and VI in *Lpar3*-deficient peri-implantation mouse uterus. *Biol Reprod.* 2011;84(2):255–65.
- Iwahashi M, Muragaki Y, Ooshima A, Nakano R. Decreased type IV collagen expression by human decidual tissues in spontaneous abortion. *J Clin Endocrinol Metab.* 1996;81(8):2925–9.
- Murphy G. Tissue inhibitors of metalloproteinases. *Genome Biol.* 2011;12(11):233.
- Curry Jr TE, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. *Endocr Rev.* 2003;24(4):428–65.
- Wang H, Wen Y, Mooney S, Li H, Behr B, Polan ML. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human preimplantation embryos. *Fertil Steril.* 2003;80 Suppl 2:736–42.
- Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. *Biochim Biophys Acta.* 2010;1803(1):55–71.
- Hammani K, Blakis A, Morsette D, Bowcock AM, Schmutte C, Henriot P, et al. Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. *J Biol Chem.* 1996;271(41):25498–505.
- Godbole G, Suman P, Gupta SK, Modi D. Decidualized endometrial stromal cell derived factors promote trophoblast invasion. *Fertil Steril.* 2011;95(4):1278–83.
- Dixon ME, Chien EK, Osol G, Callas PW, Bonney EA. Failure of decidual arteriolar remodeling in the CBA/J x DBA/2 murine model of recurrent pregnancy loss is linked to increased expression of tissue inhibitor of metalloproteinase 2 (TIMP-2). *Am J Obstet Gynecol.* 2006;194(1):113–9.

33. Chernov AV, Sounni NE, Remacle AG, Strongin AY. Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. *J Biol Chem*. 2009;284(19):12727–34.
34. Diego-Alvarez D, Ramos-Corralles C, Garcia-Hoyos M, Bustamante-Aragones A, Cantalapiedra D, Diaz-Recasens J, et al. Double trisomy in spontaneous miscarriages: cytogenetic and molecular approach. *Hum Reprod*. 2006;21(4):958–66.
35. Graham CH, Lysiak JJ, McCrae KR, Lala PK. Localization of transforming growth factor-beta at the human fetal-maternal interface: role in trophoblast growth and differentiation. *Biol Reprod*. 1992;46(4):561–72.
36. Tyson C, Harvard C, Locker R, Friedman JM, Langlois S, Lewis ME, et al. Submicroscopic deletions and duplications in individuals with intellectual disability detected by array-CGH. *Am J Med Genet*. 2005;139(3):173–85.
37. Wen J, Lopes F, Soares G, Farrell SA, Nelson C, Qiao Y, et al. Phenotypic and functional consequences of haploinsufficiency of genes from exocyst and retinoic acid pathway due to a recurrent microdeletion of 2p13.2. *Orphanet J Rare Dis*. 2013;8:100.
38. Ivanova T, Vinokurova S, Petrenko A, Eshilev E, Solovyova N, Kissel'ov F, et al. Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer. *Int J Cancer*. 2004;108(6):882–6.
39. Kim HR, Han RX, Diao YF, Park CS, Jin DI. Epigenetic characterization of the PBEF and TIMP-2 genes in the developing placentae of normal mice. *BMB Rep*. 2011;44(8):535–40.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

